In addition to the above-mentioned compensatory up-regulation [150], activation of parallel by-pass non-EGFR ERBB-signaling may also occur in TKI-treated NSCLC cells by alterations of ERBB2/3/4 genes. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.